Physician's First Watch

Physician's First Watch

Medical news from NEJM Journal Watch

May 31, 2017

By Amy Orciari Herman

Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM

Weight loss interventions for children may be just as effective when only parents attend treatment sessions as when children...

Comments (0)

By Amy Orciari Herman

Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM

The U.S. Preventive Services Task Force now says there's not enough evidence to weigh the benefits and harms of screening...

Comments (0)

May 30, 2017

By Amy Orciari Herman

Edited by David G. Fairchild, MD, MPH

Use of beta-blockers after myocardial infarction might not improve 1-year survival in patients who don't have heart failure or left ventricular systolic dysfunction, suggests an observational study in the Journal of the American College of Cardiology. U.S. guidelines currently recommend...

Comments (0)

By Amy Orciari Herman

Edited by David G. Fairchild, MD, MPH

For patients with active rheumatoid arthritis despite methotrexate therapy, adding a biologic agent (e.g., etanercept) before trying triple therapy would lead to substantial cost increases without much...

Comments (0)

By Amy Orciari Herman

Edited by David G. Fairchild, MD, MPH

Methamphetamine users who develop cardiomyopathy see symptom improvement only when they stop using the drug, according to a JACC: Heart Failure study.

Researchers in Germany studied 30...

Comments (0)

May 27, 2017

May 26, 2017

By Kelly Young

Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS

The latest version of the American Health Care Act recently passed by the U.S. House of Representatives would leave...

Comments (0)

By Amy Orciari Herman

Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS

The age-adjusted rate of death related to Alzheimer disease increased by over 50% from 1999 to 2014 — from 16.5...

Comments (0)

May 25, 2017

By the Editors

An advisory panel recommended on Wednesday that the FDA approve the breast cancer drug neratinib (to be marketed as Nerlynx),...

Comments (0)

By Amy Orciari Herman

Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM

Adjunctive treatment with cannabidiol — a nonhallucinogenic cannabinoid — may reduce seizure frequency in young people with the Dravet syndrome, according to an industry-funded...

Comments (0)

By Kelly Young

Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM

The FDA has approved pembrolizumab (Keytruda) to treat patients who have solid tumors with biomarkers known as microsatellite instability-high (MSI-H) or...

Comments (0)

Pages